Incidence and risk of hematologic toxicities in cancer patients treated with regorafenib

Regorafenib, an oral vascular endothelial growth factor receptor tyrosine-kinase inhibitor, has been approved for the treatment of several malignancies. As a non-traditional cytotoxic chemotherapeutic agent, regorafenib is often associated with hematologic toxicities. Here we searched PubMed and Emb...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Bin, Zhao, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706837/
https://www.ncbi.nlm.nih.gov/pubmed/29212191
http://dx.doi.org/10.18632/oncotarget.21217

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706837/
https://www.ncbi.nlm.nih.gov/pubmed/29212191
http://dx.doi.org/10.18632/oncotarget.21217

Ejemplares similares